The shot, developed by the Medical Research Future Fund-funded BioNTech and Inova vaccine Institute founders, is four to five times more potent than any available vaccine.
The residents who received the top dose of the vaccine used in the trial are in a “fairly typical” range, he said.
Medical Research Future Fund announced the trial process back in May, when it said it would invest $2.6 million into treatments for patients with acute and chronic diseases, including COVID-19 and diabetes, as well as managing the limited supply of protective equipment.
Still at a base of $270,000 is his most realistic long-term goal, down from a high $2.4 million funding round in 2018.
Self-sufficiency is the mostly unmet need, said Brownlee of the vaccine’s international appeal.
“This has been a major life-saving tool for a large number of people around the world.”
